{"DataElement":{"publicId":"6588326","version":"1","preferredName":"Perihilar Bile Duct Cancer AJCC Edition 8 Clinical Regional Lymph Node N Category","preferredDefinition":"Extent of the regional lymph node involvement for perihilar bile duct carcinoma based on evidence obtained from the date of cancer diagnosis until the start of definitive treatment, or within four months (whichever is shorter), using AJCC Ed. 8 criteria.","longName":"PBD_AJC8_CLN_N_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6587425","version":"1","preferredName":"Intrahepatic Large Bile Duct Neoplasm Clinical N Category","preferredDefinition":"The larger bile ducts which are located within the liver and drain bile from the smaller peripheral intrahepatic bile ducts into the right and left hepatic ducts._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","longName":"6587421v1.0:2428496v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6587421","version":"1","preferredName":"Intrahepatic Large Bile Duct Neoplasm","preferredDefinition":"The larger bile ducts which are located within the liver and drain bile from the smaller peripheral intrahepatic bile ducts into the right and left hepatic ducts.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C96803:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrahepatic Large Bile Duct","conceptCode":"C96803","definition":"The larger bile ducts which are located within the liver and drain bile from the smaller peripheral intrahepatic bile ducts into the right and left hepatic ducts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD2B5BC-6C09-06E4-E053-F662850A2B94","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2428496","version":"1","preferredName":"Clinical N Stage","preferredDefinition":"Having to do with the examination and treatment of patients.:One criteria of the TMN staging system. N refers to the extent of lymph node involvement.","longName":"C25398:C25580","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical","conceptCode":"C25398","definition":"Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"N Category","conceptCode":"C25580","definition":"One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"053C2A34-0888-693F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-11","modifiedBy":"ONEDATA","dateModified":"2005-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"7CD2BDA7-4BBD-06E8-E053-F662850AB219","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-30-19 tmt released.; 12/12/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6587601","version":"1","preferredName":"Perihilar Bile Duct Carcinoma American Joint Committee on Cancer Edition 8 N Category","preferredDefinition":"A finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to perihilar cholangiocarcinomas. Well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system. N refers to the extent of lymph node involvement._A grouping of items based on some commonality or by user defined characteristics.","longName":"6587601v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"N2","valueDescription":"Perihilar Bile Duct Cancer pN2 TNM Finding v8","ValueMeaning":{"publicId":"6587603","version":"1","preferredName":"Perihilar Bile Duct Cancer pN2 TNM Finding v8","longName":"6587603","preferredDefinition":"Perihilar bile duct cancer with four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perihilar Bile Duct Cancer pN2 TNM Finding v8","conceptCode":"C134735","definition":"Perihilar bile duct cancer with four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD52887-A784-5AFF-E053-F662850A8E40","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD52887-A79D-5AFF-E053-F662850A8E40","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"N1","valueDescription":"Perihilar Bile Duct Cancer pN1 TNM Finding v8","ValueMeaning":{"publicId":"6587605","version":"1","preferredName":"Perihilar Bile Duct Cancer pN1 TNM Finding v8","longName":"6587605","preferredDefinition":"Perihilar bile duct cancer with one to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perihilar Bile Duct Cancer pN1 TNM Finding v8","conceptCode":"C134734","definition":"Perihilar bile duct cancer with one to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD52887-A7AA-5AFF-E053-F662850A8E40","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD52887-A7C3-5AFF-E053-F662850A8E40","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"N0","valueDescription":"Perihilar Bile Duct Cancer pN0 TNM Finding v8","ValueMeaning":{"publicId":"6587607","version":"1","preferredName":"Perihilar Bile Duct Cancer pN0 TNM Finding v8","longName":"6587607","preferredDefinition":"Perihilar bile duct cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perihilar Bile Duct Cancer pN0 TNM Finding v8","conceptCode":"C134733","definition":"Perihilar bile duct cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD52887-A7D0-5AFF-E053-F662850A8E40","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD52887-A7E9-5AFF-E053-F662850A8E40","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"NX","valueDescription":"Perihilar Bile Duct Cancer pNX TNM Finding v8","ValueMeaning":{"publicId":"6587609","version":"1","preferredName":"Perihilar Bile Duct Cancer pNX TNM Finding v8","longName":"6587609","preferredDefinition":"Perihilar bile duct cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perihilar Bile Duct Cancer pNX TNM Finding v8","conceptCode":"C134732","definition":"Perihilar bile duct cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD52887-A7F6-5AFF-E053-F662850A8E40","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD52887-A80F-5AFF-E053-F662850A8E40","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6587600","version":"1","preferredName":"Perihilar Bile Duct Cancer TNM Finding v8 American Joint Committee on Cancer N Category Category","preferredDefinition":"A finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to perihilar cholangiocarcinomas. Well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.):A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:One criteria of the TNM staging system. N refers to the extent of lymph node involvement.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C134712:C39315:C25580:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perihilar Bile Duct Cancer TNM Finding v8","conceptCode":"C134712","definition":"A finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to perihilar cholangiocarcinomas. Well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"N Category","conceptCode":"C25580","definition":"One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD52887-A757-5AFF-E053-F662850A8E40","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7CD52887-A768-5AFF-E053-F662850A8E40","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"TAYLORT","dateModified":"2019-09-04","changeDescription":"8-20-19 released per MC.; 12/12/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6581918","version":"1","longName":"Bile Duct(s)","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Clinical N category","type":"Preferred Question Text","description":"Clinical N category","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7CE6581C-934F-2C50-E053-F662850A8F5B","latestVersionIndicator":"Yes","beginDate":"2018-12-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-13","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-30-19 TMT released per MC.; 12/13/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}